Results 201 to 210 of about 268,746 (338)
After the intravenous injection of biomimetic and pH/ROS‐responsive PTSK@CRM, the nanoparticles can be accumulated in tumors and release Sim and KYNase to inhibit the tumor growth, regulate the metabolism of cholesterol and Kyn, and reverse the immunosuppressive tumor microenvironment.
Jiaxin Yin +6 more
wiley +1 more source
Research progress on immune checkpoint inhibitors in intrahepatic cholangiocarcinoma. [PDF]
Yin Z, Zhang L, Li J, Tan H, Ma B.
europepmc +1 more source
Influence of the Immune Checkpoint Inhibitors on the Hemostatic Potential of Blood Plasma [PDF]
Irina Patalakh +5 more
openalex +1 more source
Heterogeneous cancer‐associated fibroblasts orchestrate dual immune microenvironments in LAGC. Abstract The potential for immunotherapy in patients with locally advanced gastric cancer (LAGC) is recently confirmed. To report the 3‐year follow‐up data are aimed from a novel clinical trial. This is a prospective single‐arm phase II trial.
Yao Lin +14 more
wiley +1 more source
Understanding the Inflammatory Aspect of Osteoarthritis: Lessons from Immune Checkpoint Inhibitors. [PDF]
Portnoy DM +5 more
europepmc +1 more source
Cancer cell‐intrinsic cholesterol promotes the S‐palmitoylation of SP1, increasing its nuclear translocation and driving the transcription and secretion of MDK, which in turn facilitates the differentiation of macrophages into a lipid‐associated phenotype.
Shirong Peng +12 more
wiley +1 more source
Hematological toxicity of immune checkpoint inhibitors: a pharmacovigilance study. [PDF]
Tan AJ +6 more
europepmc +1 more source
This study identifies platelet‐derived extracellular vesicles as key immunometabolic regulators in COVID‐19. The delivery of tRF‐His‐GTG‐1 to neutrophils activates TLR8mTOR signaling, disrupts lipophagy, and amplifies NET‐mediated inflammation. Importantly, targeting this axis restores neutrophil homeostasis, offering a potential therapeutic strategy ...
Tsai‐Ling Liao +5 more
wiley +1 more source

